Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
NeoGenomics Blood-Based Minimal Residual Disease Test Receives CE Mark
NeoGenomics subsidiary Inivata has also submitted the RaDaR test to the MolDx program in the US for reimbursement.Â
C2i Genomics, OncoDNA Enter Strategic Alliance for AI-Based Cancer Detection, Monitoring
The companies and the Gustave Roussy Institute plan to initiate a clinical trial to test the utility of escalating treatments for cancers with high risk of recurrence.
The company believes its fixed-panel, informatically guided approach can help capture the most possible patients with signs of residual or recurring cancer.
Genetron Health Q3 Revenues up 36 Percent, Firm Announces AstraZeneca MRD Partnership
The company saw the largest increase in its IVD business, driven by sales of the S5 sequencing instrument and its 8-gene Lung Cancer Assay.
Exact Sciences, Jefferson Health to Study Blood-Based Multicancer Early Detection Test
The partners will survey doctors, care coordinators, and patients on metrics like test safety and efficacy, and how to best implement multicancer testing.